Paper39682147
Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation.
Garcia KB and 13 others. Cancers (Basel), 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation. Papers, record 39682147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39682147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References136
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38831488 | Expanding Selection Criteria in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Long-term Follow-up of a National Registry and 2 Transplant Centers. | Transplantation | 2024 | https://conductscience.org/library/papers/38831488 | PubMed |
| 2 | 1328439 | Superoxide generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats. | J Leukoc Biol | 1992 | https://conductscience.org/library/papers/1328439 | PubMed |
| 3 | 37208105 | Machine perfusion of the liver and bioengineering. | J Hepatol | 2023 | https://conductscience.org/library/papers/37208105 | PubMed |
| 4 | 32217938 | Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. | Transplantation | 2020 | https://conductscience.org/library/papers/32217938 | PubMed |
| 5 | 7705789 | Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. | Hepatology | 1995 | https://conductscience.org/library/papers/7705789 | PubMed |
| 6 | 38610921 | Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38610921 | PubMed |
| 7 | 38969242 | Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study). | J Hepatol | 2025 | https://conductscience.org/library/papers/38969242 | PubMed |
| 8 | 20187107 | Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. | Hepatology | 2010 | https://conductscience.org/library/papers/20187107 | PubMed |
| 9 | 26098966 | Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. | Br J Surg | 2015 | https://conductscience.org/library/papers/26098966 | PubMed |
| 10 | 10195903 | Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. | Science | 1999 | https://conductscience.org/library/papers/10195903 | PubMed |
| 11 | 21084727 | A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. | Aging (Albany NY) | 2010 | https://conductscience.org/library/papers/21084727 | PubMed |
| 12 | 37069635 | N-acetylcysteine in the Donor, Recipient, or Both Donor and Recipient in Liver Transplantation: A Systematic Review With Meta-analysis and Trial Sequential Analysis. | Transplantation | 2023 | https://conductscience.org/library/papers/37069635 | PubMed |
| 13 | 30080954 | Liver Transplantation Today: Where We Are Now and Where We Are Going. | Liver Transpl | 2018 | https://conductscience.org/library/papers/30080954 | PubMed |
| 14 | 25383517 | Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. | Nature | 2014 | https://conductscience.org/library/papers/25383517 | PubMed |
| 15 | 35950880 | Mitochondria and ischemia reperfusion injury. | Curr Opin Organ Transplant | 2022 | https://conductscience.org/library/papers/35950880 | PubMed |
| 16 | 9415549 | Prostaglandin E1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. | Transplantation | 1997 | https://conductscience.org/library/papers/9415549 | PubMed |
| 17 | 34722716 | Ischemic Preconditioning for Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Visc Med | 2021 | https://conductscience.org/library/papers/34722716 | PubMed |
| 18 | 30967904 | Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. | World J Hepatol | 2019 | https://conductscience.org/library/papers/30967904 | PubMed |
| 19 | 23994383 | Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. | J Hepatol | 2014 | https://conductscience.org/library/papers/23994383 | PubMed |
| 20 | 36902813 | How Can Machine Perfusion Change the Paradigm of Liver Transplantation for Patients with Perihilar Cholangiocarcinoma? | J Clin Med | 2023 | https://conductscience.org/library/papers/36902813 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42945018 | ASO Author Reflections: Machine Perfusion Use and Liver Transplantation for Hepatocellular Carcinoma. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42945018 | PubMed |
| 42930145 | Machine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930145 | PubMed |
| 42886321 | Impact of Machine Perfusion on Liver Transplantation for Hepatocellular Carcinoma. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42886321 | PubMed |
| 41542223 | Outcome reporting for liver transplantation machine perfusion studies: a systematic review. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/41542223 | PubMed |
| 41301822 | Liver Machine Perfusion: Past, Present and Future Directions. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301822 | PubMed |
| 40881323 | Number of Pretransplant Therapeutic Plasma Exchange Sessions Increase the Recurrence Risk of Hepatocellular Carcinoma in ABO-Incompatible Living Donor Liver Transplantation. | Transpl Int | 2025 | https://conductscience.org/library/papers/40881323 | PubMed |
| 40672061 | A novel miRNA-based model for predicting the 3-year recurrence risk of hepatocellular carcinoma following liver transplantation. | J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40672061 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39682147
GET https://conductscience.org/api/papers/v1/39682147/references?page=2